Does small-molecule inhibition of MuRF1 attenuate skeletal muscle atrophy and dysfunction in an in vivo model of cardiac cachexia?
A novel small-molecule inhibitor of MuRF1 shows preclinical promise in attenuating skeletal muscle wasting and contractile dysfunction associated with cardiac cachexia.
We identified a novel compound directed to MuRF1's central myofibrillar protein recognition domain. This compound attenuated in vivo muscle wasting and contractile dysfunction in cardiac cachexia by protecting de novo protein synthesis and by down-regulating apoptosis and ubiquitin-proteasome-dependent proteolysis.
Bowen et al. (Fri,) studied this question.